Litcius/Paper detail

Endoluminal ultrasound versus magnetic resonance imaging in assessment of rectal cancer after neoadjuvant therapy

Elsayed Ghoneem, Ahmed Shekeib Abdein Shabana, Mohamed El Sherbini, Mohammad Zuhdy, Osama Eldamshety, Mohamed Gouda, Ahmed El Shamy, Gehad A. Saleh, Ahmed Saleh

2022BMC Gastroenterology14 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Accurate rectal tumor staging guides the choice of treatment options. EUS and MRI are the main modalities for staging. AIM OF THE WORK: To compare the performance of EUS and MRI for loco-regional staging of anorectal cancer after neo-adjuvant therapy. METHODS: Seventy-three (37 male, 36 female) patients with rectal cancer after neo-adjuvant chemoradiotherapy were enrolled. Histopathological staging after surgery were used as reference for comparing the yield of loco-regional staging for EUS and MRI. EUS and MRI were done 1 month after completion of neo-adjuvant therapy. RESULTS: Regarding post-surgical T staging, eight patients had early tumor (T2 = 16 and T1 = 9) and thirty six were locally advanced (T3 = 36), while N staging, forty patients with negative nodes and 33 were positive (N1 = 22 and N2 = 11). Comparing EUS to MRI, it showed a higher sensitivity (95.7% vs. 78.7%), specificity (84.6% vs. 68.0%) and accuracy (91.8% vs. 75.3%) for staging early and locally advanced tumor. Also, it had a higher sensitivity (78.8% vs. 69.7%), specificity (75.0% vs. 65.0%) and accuracy (76.7% vs. 67.1%) for detection of lymph nodes. CONCLUSION: EUS appears to be more accurate than MRI in loco-regional staging of rectal carcinoma after neo-adjuvant therapy.

Topics & Concepts

MedicineMagnetic resonance imagingColorectal cancerNeoadjuvant therapyRadiologyHepatologyEndoscopic ultrasoundAdjuvant therapyRadiation therapyChemoradiotherapyCancerInternal medicineBreast cancerColorectal Cancer Surgical TreatmentsColorectal and Anal CarcinomasEsophageal Cancer Research and Treatment
Endoluminal ultrasound versus magnetic resonance imaging in assessment of rectal cancer after neoadjuvant therapy | Litcius